10-Q: Precision Optics Reports Q2 2025 Results: Revenue Declines Amid Shift in Product Mix

Precision Optics Corporation reports a decrease in revenue for the quarter ended December 31, 2024, primarily due to a shift in product sales mix and decreased demand for engineering design services.

Summary

• Precision Optics Corporation reported total revenues of $4,526,907 for the quarter ended December 31, 2024, a decrease of 6.2% compared to $4,824,289 for the same period in the prior year.
• For the six months ended December 31, 2024, total revenues were $8,723,960, a decrease of 4.6% compared to $9,145,544 for the same period in the prior year.
• Revenue from Engineering Design Services decreased by 46.8% for the quarter and 26.7% for the six-month period, attributed to decreased demand, increased internal R&D, and milestone delays.
• Optical Components revenue increased by 50.8% for the quarter and 30.4% for the six-month period due to new defense/aerospace and medical device programs.
• Finished Products and Assemblies revenue decreased by 41.7% for the quarter and 45.0% for the six-month period due to lower demand and order fulfillment timing.
• Gross margin decreased to 23.6% for the quarter and 25.1% for the six-month period, driven by changes in the product sales mix.
• R&D expenses increased to $317,747 for the quarter and $718,406 for the six-month period, supporting product improvements and new technology development.
• SG&A expenses decreased by 14.0% to $1,662,216 for the quarter but increased 1.0% to $3,625,828 for the six-month period.
• The company had $900,000 in borrowings outstanding on its line of credit as of December 31, 2024, with $350,000 remaining available.
• A six-month period of interest-only payments on term loans was agreed upon with the lender from October 15, 2024, through March 15, 2025.
• The company raised $1.4 million in gross proceeds from a registered direct common stock offering, resulting in net proceeds of $1,204,542.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positives such as growth in Optical Components revenue and a successful capital raise, the overall financial performance is weaker than the previous year, with declining revenues and gross margins. The company also faces competitive pressures and the need for ongoing innovation.

Positives

• Optical Components revenue increased significantly due to new defense/aerospace and medical device programs.
• The company secured a six-month interest-only payment period on its term loans, providing short-term financial relief.
• The company raised $1.2 million in net proceeds through a registered direct common stock offering.
• The company is registered to the ISO 9001:2015 and ISO 13485:2016 Quality Standards and complies with the FDA Good Manufacturing Practices.

Negatives

• Total revenues decreased for both the quarter and the six-month period.
• Engineering Design Services revenue experienced a substantial decline.
• Gross margin decreased, impacting profitability.
• The company did not meet the minimum annual debt service coverage ratio covenant as of June 30, 2024, requiring a waiver from the lender.
• The company reported a net loss of $(969,681) and $(2,280,928) for the three and six months ended December 31, 2024 respectively.

Risks

• The markets in which the company does business are highly competitive.
• The company's future success depends on its ability to develop new optical products and services.
• Competition among medical device companies is increasing with multiple companies now pursuing less expensive, procedure specific robotic systems.
• The company may be required to raise external financing in the short-term.
• Matters arising in the ordinary course of business for which the company is or could become involved in litigation may have a material adverse effect on our business, financial condition or results of operations.

Future Outlook

Management believes that the company's available cash, cash equivalents, cash generated from operations, availability on the line of credit, and ability to raise funds in the capital markets will be sufficient to provide for the company's working capital and capital expenditure requirements for at least 12 months from the date of this filing, but may be required to raise external financing in the short-term.

Management Comments

• We expect our customer pipeline to continue to expand as development projects transition to production orders and new customer projects enter the development phase.
• Current sales and marketing activities are intended to broaden awareness of the benefits of our new technology platforms and our successful application of these new technologies to medical device projects requiring surgery-grade visualization from millimeter sized devices and 3D endoscopy, including single-use products and assemblies.

Industry Context

The company operates in the competitive markets of medical devices and custom optical components, facing competition from both domestic and foreign companies, including those with greater resources. The demand for smaller and more enhanced imaging systems in the surgical community is driving market trends.

Comparison to Industry Standards

• It is difficult to provide a direct comparison to industry standards without specific competitor data.
• However, the company's focus on micro-precision optics and single-use endoscopes aligns with the trend towards minimally invasive and disposable medical devices.
• The company's ISO certifications (9001:2015 and 13485:2016) indicate a commitment to quality management systems, which is a standard requirement in the medical device industry.
• The company's reliance on a few key customers and its exposure to fluctuations in demand are common risks in the custom manufacturing sector.

Stakeholder Impact

• Shareholders may be concerned about the declining revenues and gross margins.
• Employees may be affected by the company's performance and future prospects.
• Customers may benefit from the company's ongoing innovation and development of new products.
• Creditors will be monitoring the company's financial performance and ability to meet its debt obligations.

Next Steps

• Continue to seek and obtain product-related design and development contracts with customers.
• Selectively invest own funds on research and development, particularly in the areas of MicroprecisionTM optics, micro medical cameras, illumination, single-use endoscopes, and 3D endoscopes.
• Broaden awareness of the benefits of new technology platforms and successful application of these new technologies to medical device projects.

Key Dates